Squarepoint’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-25,100
Closed -$1.09M 4790
2025
Q3
$1.09M Buy
+25,100
New +$1.01M ﹤0.01% 2620

Other funds holding RNAM

Squarepoint's RNAM Position: Q1 2026 in Review

Squarepoint sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 868,200 shares — an estimated $62.6M sold.

Squarepoint first reported a position in RNAM in Q4 2020 and held it in 14 quarters. The position peaked at $62.6M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Squarepoint reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 868,200 Avidity Biosciences shares in Q1 2026, an estimated $62.6M.
  • Squarepoint first reported a position in Avidity Biosciences in Q4 2020 and held it in 14 quarters.
  • Squarepoint's Avidity Biosciences position peaked at $62.6M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.